Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following ...

Scientists have zeroed in on a critical weak spot behind a rare but devastating brain autoimmune disorder often known as ...

MIRA Pharmaceuticals has completed dosing in its Phase I clinical trial of Ketamir-2, the company’s selective oral N-methyl-D-aspartate (NMDA) receptor modulator, assessing its safety, tolerability, ...

SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing therapeutics based on its ...

A protein called klotho is reshaping how scientists understand cognitive aging, offering the first clear molecular link ...

Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis ...

Scientists have long searched for ways to treat Alzheimer’s disease, the most common form of dementia. Chief among these ...

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of around 20% during the forecast period. This rapid expansion is primarily fueled by the rising prevalence of ...

While companies developing drugs to treat Alzheimer's disease have spent decades and many billions of dollars targeting ...

For over thirty years, researchers have primarily studied the accumulation of amyloid beta proteins in the brains of Alzheimer’s patients. They also focus on how that component negatively impacts ...